Powered by healthtechmovers.com
According to healthtechmovers.com, there are a few trending healthtech stocks that have recently received buy ratings and showing positive investor sentiment, as well as news headlines. With that said, the editors over at healthtechmovers.com, are adding the stocks below to their healthtech stock watchlist. That staff here at delrayresearch.com, will continue to monitor these healthtech companies to see if the momentum continues. DelrayResearch.com is also looking into these tickers DAWN, COGT, RMD, BSX, RACE, RTX..
Recent AXSM Stock Price: $40.64
Summary: Axsome Therapeutics is a biopharmaceutical company focused on developing novel therapies for the management of central nervous system (CNS), disorders for which there are limited treatment options available.
Charles Duncan analyst at Cantor Fitzgerald reiterates coverage on Axsome Therapeutics (AXSM) stock in the energy sector with a Buy rating and has set AXSM's stock price target at $ 64.
TipRanks.com reports that Axsome Therapeutics currently has 11 analysts offering 12-month price targets on AXSM and the consensus is a Moderate Buy rating with an average stock price target of $65.44. The most recent AXSM stock price we have is $40.64 and we are not making any AXSM forecasts at this time.
In addition, TradingView issued a Buy rating for AXSM over the next month, Barchart.com has a Weak sell rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on AXSM. delrayresearch.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on AXSM, please click here >>
Blueprint Medicines, BPMC
Recent BPMC Stock Price: $49.93
Summary: Blueprint Medicines Corporation is a biopharmaceutical company focused on developing the potentially transformational precision medicines to address patients with genomically defined cancers and rare diseases.
David Lebovitz analyst at Citigroup reiterates coverage on Blueprint Medicines (BPMC) stock in the energy sector with a Sell rating and has set BPMC's stock price target at $ 41.
TipRanks.com reports that Blueprint Medicines currently has 10 analysts offering 12-month price targets on BPMC and the consensus is a Moderate Buy rating with an average stock price target of $79.78. The most recent BPMC stock price we have is $49.93 and we are not making any BPMC forecasts at this time.
In addition, TradingView issued a n/a rating for BPMC over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on BPMC. delrayresearch.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on BPMC, please click here >>
Roivant Sciences, ROIV
Recent ROIV Stock Price: $4.42
Summary: Roivant Sciences is a biopharmaceutical company dedicated to improving the delivery of healthcare to patients. Roivant Sciences, formerly known as Montes Archimedes Acquisition Corp., is based in NEW YORK.
Douglas Tsao analyst at H.C. Wainwright reiterates coverage on Roivant Sciences (ROIV) stock in the energy sector with a Buy rating and has set ROIV's stock price target at $ 14.
TipRanks.com reports that Roivant Sciences currently has 8 analysts offering 12-month price targets on ROIV and the consensus is a Strong Buy rating with an average stock price target of $10.83. The most recent ROIV stock price we have is $4.42 and we are not making any ROIV forecasts at this time.
In addition, TradingView issued a Buy rating for ROIV over the next month, Barchart.com has a n/a rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on ROIV. delrayresearch.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on ROIV, please click here >>
BioNTech SE, BNTX
Recent BNTX Stock Price: $157.50
Summary: BioNTech SE is a biotechnology company. It develops and commercializes immunotherapies for cancer and other diseases. BioNTech SE is based in Mainz, Germany.
Emmanuel Papadakis analyst at Deutsche Bank reiterates coverage on BioNTech SE (BNTX) stock in the energy sector with a Hold rating and has set BNTX's stock price target at $ 180.
TipRanks.com reports that BioNTech SE currently has 10 analysts offering 12-month price targets on BNTX and the consensus is a Moderate Buy rating with an average stock price target of $236.70. The most recent BNTX stock price we have is $157.50 and we are not making any BNTX forecasts at this time.
In addition, TradingView issued a Buy rating for BNTX over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on BNTX. delrayresearch.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on BNTX, please click here >>
89bio, ETNB
Recent ETNB Stock Price: $3.24
Summary: 89bio Inc. is clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate, BIO89-100, is being developed for the treatment of nonalcoholic steatohepatitis. 89bio Inc. is headquartered in San Francisco.
Jay Olson analyst at Oppenheimer reiterates coverage on 89bio (ETNB) stock in the energy sector with a Buy rating and has set ETNB's stock price target at $ 15.
TipRanks.com reports that 89bio currently has 9 analysts offering 12-month price targets on ETNB and the consensus is a Strong Buy rating with an average stock price target of $26.25. The most recent ETNB stock price we have is $3.24 and we are not making any ETNB forecasts at this time.
In addition, TradingView issued a n/a rating for ETNB over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on ETNB. delrayresearch.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on ETNB, please click here >>
Kezar Life Sciences, KZR
Recent KZR Stock Price: $9.29
Summary: Kezar Life Sciences, Inc. is a bio-technology company. It discovers and develops molecule therapeutics and medicines such as protein homeostasis for autoimmune disorders. The company's product pipeline consists of KZR-616 which is in clinical stage. Kezar Life Sciences, Inc. is headquartered in South San Francisco, California.
Maury Raycroft analyst at Jefferies reiterates coverage on Kezar Life Sciences (KZR) stock in the energy sector with a Buy rating and has set KZR's stock price target at $ 20.
TipRanks.com reports that Kezar Life Sciences currently has 6 analysts offering 12-month price targets on KZR and the consensus is a Strong Buy rating with an average stock price target of $19.67. The most recent KZR stock price we have is $9.29 and we are not making any KZR forecasts at this time.
In addition, TradingView issued a Buy rating for KZR over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on KZR. delrayresearch.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on KZR, please click here >>
The editors at delrayresearch.com use a variety of research tools to generate our watchlists and research reports. One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star RankingTM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
Click here to join thousands of investors who have already signed up for a free subscription to consumer staples stocks newsletter PoliticsAndMyPortfolio.com.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================